Trédan, Olivier

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,744

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 1,137

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Gómez Pardo, P., et al. (2023) · The Lancet

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 496

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Goetz, M. P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I. H., Campone, M., Chen, S.-C., Manso, L. M., Paluch-Shimon, S., et al. (2024) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 238

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Ferrari, A., Vincent-Salomon, A., Pivot, X., Sertier, A.-S., Thomas, E., Tonon, L., Boyault, S., Mulugeta, E., Treilleux, I., MacGrogan, G., et al. (2016) · Nature Communications

HER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

Cited by 150